Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability

Journal of Thrombosis and Thrombolysis

Volumn 36, Issue 1, 2013, Pages 31-41

  Speich, Henry E ^a   Furman, Ronit R ^b   Lands, Lindsey T ^a   Moodie, Geoffrey D ^b   Jennings, Lisa K ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Atrium Medical Corporation   (United States)

Author keywords

Abciximab; Arterial thrombosis; Eptifibatide; GPIIb IIIa antagonists; Intracoronary administration; Platelets

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; THROMBIN;

ARTICLE; BALLOON CATHETER; BLOOD CLOT LYSIS; COMPUTATIONAL FLUID DYNAMICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; IN VITRO STUDY; PRIORITY JOURNAL; SIMULATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBUS; VASCULAR PATENCY;

ANTIBODIES, MONOCLONAL; ANTITHROMBINS; CORONARY VESSELS; FEMALE; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 84879199556     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0814-7     Document Type: Article

References (55)

1. Jennings LK (2009) Role of platelets in atherothrombosis. Am J Cardiol 103(3 Suppl):4A-10A. doi: 10.1016/j.amjcard.2008.11.017
2. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ (1998) Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98(25):2829-2835
3. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Baldazzi F, Dall'Ara G, Nardini P, Gianstefani S, Guastaroba P, Grilli R, Branzi A (2009) Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J 30(1):33-43. doi: 10.1093/eurheartj/ehn480
4. Topol EJ, Byzova TV, Plow EF (1999) Platelet GPIIb-IIIa blockers. Lancet 353(9148):227-231. doi: 10.1016/S0140-6736(98)11086-3
5. Lincoff AM, Califf RM, Topol EJ (2000) Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 35(5):1103-1115
6. Coller BS, Shattil SJ (2008) The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112(8):3011-3025. doi: 10.1182/blood-2008-06-077891
7. Collet JP, Montalescot G, Lesty C, Soria J, Mishal Z, Thomas D, Soria C (2001) Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 21(1):142-148
8. Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL (2002) An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 87(6):1020-1025
9. Collet JP, Montalescot G, Lesty C, Weisel JW (2002) A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res 90(4):428-434
10. Moser M, Bertram U, Peter K, Bode C, Ruef J (2003) Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 41(4):586-592
11. Goto S, Tamura N, Ishida H (2004) Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 44(2):316-323
12. Speich HE, Earhart AD, Hill SN, Cholera S, Kueter TJ, Smith JN, White MM, Jennings LK (2009) Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab. J Thromb Haemost 7(6):983-991. doi: 10.1111/j.1538-7836.2009.03432.x
13. Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ (2001) Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther 297(2):496-500
14. Robson R, White H, Aylward P, Frampton C (2002) Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 71(6):433-439. doi: 10.1067/mcp.2002.124522
15. Gilchrist IC (2003) Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet 42(8):703-720
16. Gretler DD, Guerciolini R, Williams PJ (2004) Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin Ther 26(3):390-398
17. Koster A, Spiess B, Jurmann M, Dyke CM, Smedira NG, Aronson S, Lincoff MA (2006) Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial. Anesth Analg 103(3):540-544. doi: 10.1213/01.ane.0000226098. 95698.0f
18. Deibele AJ, Kirtane AJ, Pinto DS, Lucca MJ, Neva C, Shui A, Murphy SA, Tcheng JE, Gibson CM (2006) Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis 22(1):47-50. doi: 10.1007/s11239-006-7454-8
19. Cortese B, Picchi A, Micheli A, Limbruno U (2009) Intracoronary bivalirudin for no reflow reversal: a second chance to treat this disorder? J Thromb Thrombolysis 28(1):74-76. doi: 10.1007/s11239-008-0243-9
20. Speich HE, Grgurevich S, Kueter TJ, Earhart AD, Slack SM, Jennings LK (2008) Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress. Am J Physiol Cell Physiol 295(4):C1045-C1054
21. Slack SM, Turitto VT (1993) Chapter 2 Fluid dynamic and hemorheologic considerations. Cardiovasc Pathol 2(3 SUPPL.):11-21
22. Slack SM, Turitto VT (1994) Flow chambers and their standardization for use in studies of thrombosis. On behalf of the subcommittee on rheology of the scientific and standardization committee of the ISTH. Thromb Haemost 72(5):777-781
23. Slack SM, Turitto VT (1993) Fluid dynamic and hemorheologic considerations. Cardiovasc Pathol 2(3):S11-S21
24. Collet JP, Montalescot G, Lesty C, Mishal Z, Soria J, Choussat R, Drobinski G, Soria C, Pinton P, Barragan P, Thomas D (2001) Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 103(19):2328-2331
25. Bennett JS (2001) Platelet-fibrinogen interactions. Ann N Y Acad Sci 936:340-354
26. Hu DD, White CA, Panzer-Knodle S, Page JD, Nicholson N, Smith JW (1999) A new model of dual interacting ligand binding sites on integrin alphaIIbbeta3. J Biol Chem 274(8):4633-4639
27. Frojmovic M, Labarthe B, Legrand C (2005) Inhibition and reversal of platelet aggregation by alphaIIbbeta3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban. Br J Haematol 131(3):348-355
28. Springer TA, Zhu J, Xiao T (2008) Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3. J Cell Biol 182(4):791-800. doi: 10.1083/jcb.200801146
29. Hantgan RR, Stahle MC, Lord ST (2010) Dynamic regulation of fibrinogen: integrin alphaIIbbeta3 binding. Biochemistry 49(43):9217-9225. doi: 10.1021/bi1009858
30. Artoni A, Li J, Mitchell B, Ruan J, Takagi J, Springer TA, French DL, Coller BS (2004) Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci USA 101(36):13114-13120. doi: 10.1073/pnas.04042011010404201101
31. Schror K, Weber AA (2003) Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 15(2):71-80
32. Jirouskova M, Jaiswal JK, Coller BS (2007) Ligand density dramatically affects integrin alpha IIb beta 3-mediated platelet signaling and spreading. Blood 109(12):5260-5269. doi: 10.1182/blood-2006-10-054015
33. Marguerie GA, Edgington TS, Plow EF (1980) Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 255(1):154-161
34. Maxwell MJ, Westein E, Nesbitt WS, Giuliano S, Dopheide SM, Jackson SP (2007) Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation. Blood 109(2):566-576. doi: 10.1182/blood-2006-07-028282
35. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, Carberry J, Fouras A, Jackson SP (2009) A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 15(6):665-673. doi: 10.1038/nm.1955
36. Jackson SP, Nesbitt WS, Westein E (2009) Dynamics of platelet thrombus formation. J Thromb Haemost 7(Suppl 1):17-20. doi: 10.1111/j.1538-7836.2009. 03401.x
37. Munnix IC, Cosemans JM, Auger JM, Heemskerk JW (2009) Platelet response heterogeneity in thrombus formation. Thromb Haemost 102(6):1149-1156. doi: 10.1160/TH09-05-0289
38. Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, Seidl K, Schroder R, Schneider S, Senges J (2005) Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 26(19):1971-1977
39. Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr, Dua V, Garringer J, Giri S, Caputo RP (2003) Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 92(8):977-980
40. Gyongyosi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, Hodl R, Gaul G, Bonner G, Wojta J, Laggner A, Glogar D, Huber K (2004) Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J 25(23):2125-2133
41. van 't Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, Petronio S, Marcel Gosselink AT, Jap W, Hollak F, Hoorntje JC, Suryapranata H, Dambrink JH, Zijlstra F (2004) Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 25(10):837-846
42. Godicke J, Flather M, Noc M, Gyongyosi M, Arntz HR, Grip L, Gabriel HM, Huber K, Nugara F, Schroder J, Svensson L, Wang D, Zorman S, Montalescot G (2005) Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J 150(5):1015
43. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F (2008) Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358(6):557-567. doi: 10.1056/NEJMoa0706416
44. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F (2008) Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 371(9628):1915-1920. doi: 10.1016/S0140-6736(08)60833-8
45. Hansen PR, Iversen A, Abdulla J (2010) Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol 22(6):278-282
46. Friedland S, Eisenberg MJ, Shimony A (2011) Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol 108(9):1244-1251. doi: 10.1016/j.amjcard.2011.06.039
47. Thiele H, Wohrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S, Schuler G (2012) Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 379(9819):923-931. doi: 10.1016/S0140-6736(11)61872-2
48. Bertrand OF, Jolly S (2012) AIDA STEMI: no benefit for intracoronary abciximab. Lancet 379(9819):875-877. doi: 10.1016/S0140-6736(12)60079-8
49. Prati F, Capodanno D, Pawlowski T, Ramazzotti V, Albertucci M, La Manna A, Di Salvo M, Gil RJ, Tamburino C (2010) Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. JACC Cardiovasc Interv 3(9):928-934. doi: 10.1016/j.jcin.2010.05.017
50. Deibele AJ, Michael Gibson C (2011) Intracoronary delivery of eptifibatide with the ClearWay(R) RX infusion catheter. Catheter Cardiovasc Interv 77(2):222-227. doi: 10.1002/ccd.22760
51. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM (2012) Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. doi: 10.1001/jama.2012.421
52. Sardella G, Sangiorgi GM, Mancone M, Colantonio R, Donahue M, Politi L, Ducci CB, Carbone I, Francone M, Ligabue G, Fiocchi F, Di Roma A, Benedetti G, Lucisano L, Stio RE, Agati L, Modena MG, Genuini I, Fedele F, Gibson M (2010) A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale. J Cardiovasc Med (Hagerstown) 11(7):529-535. doi: 10.2459/JCM.0b013e3283341c1c
53. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355(21):2203-2216. doi: 10.1056/NEJMoa062437
54. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295(13):1531-1538. doi: 10.1001/jama.295.13. joc60034
55. Lincoff AM, Steinhubl SR, Manoukian SV, Chew D, Pollack CV Jr, Feit F, Ware JH, Bertrand ME, Ohman EM, Desmet W, Cox DA, Mehran R, Stone GW (2008) Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. JACC Cardiovasc Interv 1(6):639-648. doi: 10.1016/j.jcin.2008.10.004